EA036922B1 - Состав церитиниба - Google Patents

Состав церитиниба Download PDF

Info

Publication number
EA036922B1
EA036922B1 EA201692310A EA201692310A EA036922B1 EA 036922 B1 EA036922 B1 EA 036922B1 EA 201692310 A EA201692310 A EA 201692310A EA 201692310 A EA201692310 A EA 201692310A EA 036922 B1 EA036922 B1 EA 036922B1
Authority
EA
Eurasian Patent Office
Prior art keywords
tablet
ceritinib
pharmaceutical composition
weight
binder
Prior art date
Application number
EA201692310A
Other languages
English (en)
Russian (ru)
Other versions
EA201692310A1 (ru
Inventor
Себастьен Брелль
Зимон Энсслин
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA036922(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201692310A1 publication Critical patent/EA201692310A1/ru
Publication of EA036922B1 publication Critical patent/EA036922B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
EA201692310A 2014-05-29 2015-05-27 Состав церитиниба EA036922B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29
PCT/IB2015/053966 WO2015181739A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation

Publications (2)

Publication Number Publication Date
EA201692310A1 EA201692310A1 (ru) 2017-04-28
EA036922B1 true EA036922B1 (ru) 2021-01-15

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692310A EA036922B1 (ru) 2014-05-29 2015-05-27 Состав церитиниба

Country Status (27)

Country Link
US (4) US20170112834A1 (OSRAM)
EP (1) EP3148513B1 (OSRAM)
JP (3) JP6679578B2 (OSRAM)
KR (1) KR20170008239A (OSRAM)
CN (1) CN106456640B (OSRAM)
AR (1) AR100625A1 (OSRAM)
AU (3) AU2015265470A1 (OSRAM)
BR (1) BR112016027580A8 (OSRAM)
CA (1) CA2948291A1 (OSRAM)
CL (1) CL2016003047A1 (OSRAM)
DK (1) DK3148513T3 (OSRAM)
EA (1) EA036922B1 (OSRAM)
EC (1) ECSP16096826A (OSRAM)
ES (1) ES2792574T3 (OSRAM)
HU (1) HUE048950T2 (OSRAM)
IL (1) IL248835B (OSRAM)
MX (1) MX373624B (OSRAM)
PE (1) PE20170313A1 (OSRAM)
PH (1) PH12016502272A1 (OSRAM)
PL (1) PL3148513T3 (OSRAM)
PT (1) PT3148513T (OSRAM)
SG (1) SG11201609208UA (OSRAM)
SI (1) SI3148513T1 (OSRAM)
TN (1) TN2016000484A1 (OSRAM)
TW (1) TWI721946B (OSRAM)
UY (1) UY36140A (OSRAM)
WO (1) WO2015181739A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015265470A1 (en) 2014-05-29 2016-11-24 Novartis Ag Ceritinib formulation
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
PE20071315A1 (es) * 2006-03-06 2008-02-14 Wyeth Corp Formulaciones de compuestos derivados de fenilo y procesos de preparacion para tabletas que contienen dichos compuestos
US20090239920A1 (en) 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
BRPI0722383A2 (pt) * 2006-12-08 2012-06-05 Irm Llc compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
SI2334202T1 (sl) 2008-09-04 2012-04-30 Cargill Inc Tabletiranje eritritola
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
BR112012003631A2 (pt) 2009-08-18 2015-09-01 Gargill Inc "produção de comprimidos de eritritol e isomalte."
JP5596799B2 (ja) 2010-05-11 2014-09-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤
JP2013536694A (ja) 2010-09-07 2013-09-26 カーギル インコーポレイテッド 凝固糖アルコール混合物
AU2015265470A1 (en) 2014-05-29 2016-11-24 Novartis Ag Ceritinib formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THOMAS H. MARSILJE, WEI PEI, BEI CHEN, WENSHUO LU, TETSUO UNO, YUNHO JIN, TAO JIANG, SUNGJOON KIM, NANXIN LI, MARKUS WARMUTH, YELE: "Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro- N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N 4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Pha", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 56, no. 14, 25 July 2013 (2013-07-25), pages 5675 - 5690, XP055145299, ISSN: 00222623, DOI: 10.1021/jm400402q *

Also Published As

Publication number Publication date
US20200009141A1 (en) 2020-01-09
AU2018203007B2 (en) 2019-07-18
CN106456640B (zh) 2021-05-14
US11000523B2 (en) 2021-05-11
JP2022078236A (ja) 2022-05-24
JP2020114834A (ja) 2020-07-30
IL248835B (en) 2020-05-31
TW201613580A (en) 2016-04-16
ECSP16096826A (es) 2018-04-30
PT3148513T (pt) 2020-05-27
MX373624B (es) 2020-05-22
CL2016003047A1 (es) 2017-04-07
BR112016027580A8 (pt) 2021-06-29
DK3148513T3 (da) 2020-05-25
US20210154194A1 (en) 2021-05-27
HUE048950T2 (hu) 2020-09-28
JP2017520619A (ja) 2017-07-27
PE20170313A1 (es) 2017-04-18
WO2015181739A1 (en) 2015-12-03
EP3148513A1 (en) 2017-04-05
EA201692310A1 (ru) 2017-04-28
AU2018203007A1 (en) 2018-05-17
PL3148513T3 (pl) 2020-08-24
AR100625A1 (es) 2016-10-19
AU2019232937B2 (en) 2020-10-15
KR20170008239A (ko) 2017-01-23
BR112016027580A2 (pt) 2017-08-15
MX2016015736A (es) 2017-03-16
AU2015265470A1 (en) 2016-11-24
US20190022095A1 (en) 2019-01-24
SI3148513T1 (sl) 2020-07-31
ES2792574T3 (es) 2020-11-11
US12357630B2 (en) 2025-07-15
UY36140A (es) 2016-01-08
SG11201609208UA (en) 2016-12-29
JP7084955B2 (ja) 2022-06-15
PH12016502272A1 (en) 2017-02-06
US20170112834A1 (en) 2017-04-27
CN106456640A (zh) 2017-02-22
TN2016000484A1 (en) 2018-04-04
CA2948291A1 (en) 2015-12-03
IL248835A0 (en) 2017-01-31
EP3148513B1 (en) 2020-02-26
TWI721946B (zh) 2021-03-21
AU2019232937A1 (en) 2019-10-10
JP6679578B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
US12357630B2 (en) Ceritinib formulation
CN119112820A (zh) 来那度胺的口服用片剂组合物
WO2015032873A1 (en) High-load pharmaceutical compositions comprising abiraterone acetate
US20140335176A1 (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing
US20200009098A1 (en) Eflornithine and sulindac, fixed dose combination formulation
WO2013189305A1 (zh) 缬沙坦氨氯地平复方固体制剂及其制备方法
EP2594269A1 (en) Controlled release nucleated tablet
WO2008068778A2 (en) Extended release pharmaceutical composition of pramipexole
TWI651085B (zh) Ｎ－［５－［２－（３，５－二甲氧基苯基）乙基］－２ｈ－吡唑－３－基］－４－［（３ｒ，５ｓ）－３，５－二甲基哌－１－基］苯甲醯胺之醫藥調配物
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
WO2022042646A1 (zh) 盐酸鲁拉西酮组合物及其制备方法
HK1229715B (en) Ceritinib formulation
HK1229715A1 (en) Ceritinib formulation
TW202339723A (zh) 一種固體藥物組合物
Petrovic et al. An investigation into effects of in vitro Test condition on the release properties of theophylline from HPMC matrices using factorial design
CN105636580A (zh) 包含1-[6-(吗啉-4-基)嘧啶-4-基]-4-(1h-1,2,3-三唑-1-基)-1h-吡唑-5-醇钠的药物剂型
Gupta Formulation Development And Evalution Of Immediate Release Tablet of Anti Hypertensive Drug Olmesartan Medoxomile.
HU231592B1 (hu) Favipiravir tartalmú gyógyszerkészítmény, ennek előállítása és alkalmazása
EP3041462A1 (en) High-load pharmaceutical compositions comprising abiraterone acetate

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM